Das Medizinportal     Aktuelles für medizinische Fachkreise

Das Medizinportal     Aktuelles für medizinische Fachkreise


Medikamentöse Therapie des Ovarialkarzinoms

K. Seck und B. Schmalfeldt, Hamburg (S. 9)


  1. Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg) (2013) Krebs in Deutschland 2009/ 2010. Häufigkeiten und Trends. 9. Auflage
  2. du Bois A et al. (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6): 1234–44.
  3. du Bois A et al. (2005) Ovarialkarzinom – Versorgungsstruktur und -qualität in Deutschland 2001–2004. Der Frauenarzt 46(7): 560–567
  4. Trimbos et al.; Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.J Natl Cancer Inst 2010;102:982–987 
  5. Winter-Roach BA, et al. (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. CochraneDatabase Syst Rev. (1): CD004706.].
  6. Deutsche Krebsgesellschaft (2013) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. Version 1.0 – Juni 2013. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V., Zuckschwerdt Verlag GmbH
  7. Du Bois et al.; A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320–30
  8. Burger RA et al. (2011) Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med 365: 2473–2483
  9. Perren TJ et al. for the ICON7 Investigators (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med. 365: 2484–96
  10. Pujade-Lauraine E et al. (2013) ICON 7: Final overall Survival results in the GCIG Phase III randomised trial of Bevacizumab in newly diagnosed Ovarian cancer. Abstract at the 18th Meeting of the European Society of Gynecologic Cancer 2013. Int J Gynecol Cancer 13 (8). Suppl 1.
  11. Pignata S et al.: Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncoloy Volume 15, No. 4, p396–405, April 2014
  12. www.gcig.igcs.org/London%202013/OV_GINECO_PAOLA_1_V3.pdf
  13. du Bois A, et al.: The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 15: 1234-1244
  14. Aghajanjan et al, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. 
  15. Poveda et al.: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011 Jan;22(1):39-48.
  16. Ledermann J et al. (2012) Olaprib maintenance therapy in platinum sensitive relapsed ovarian cacner. N Eng J Med 366: 1382–92
  17. Ledermann J, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
  18. Liu J, et al. J Clin Oncol 32:5s, 2014 (suppl; abstr LBA5500)
  19. Pujade-Lauraine E., et al: Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. JCO March 17, 2014

Primär systemische Therapie des Mammakarzinom

A.        Hartkopf, Tübingen (S. 26)


  1. Rastogi, P., S.J. Anderson, H.D. Bear, C.E. Geyer, M.S. Kahlenberg, A. Robidoux, R.G. Margolese, J.L. Hoehn, V.G. Vogel, S.R. Dakhil, D. Tamkus, K.M. King, E.R. Pajon, M.J. Wright, J. Robert, S. Paik, E.P. Mamounas and N. Wolmark. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 2008. 26(5): p. 778-85.
  2. van Nes, J.G., H. Putter, J.P. Julien, M. Tubiana-Hulin, M. van de Vijver, J. Bogaerts, M. de Vos, C.J. van de Velde and E. Cooperating Investigators of the. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat, 2009. 115(1): p. 101-13.
  3. Untch, M., G.E. Konecny, S. Paepke and G. von Minckwitz. Current and future role of neoadjuvant therapy for breast cancer. Breast, 2014. 23(5): p. 526-37.
  4. Cortazar, P., L. Zhang, M. Untch, K. Mehta, J.P. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S.M. Swain, T. Prowell, S. Loibl, D.L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E.P. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P.A. Fasching, L. Slaets, S. Tang, B. Gerber, C.E. Geyer, Jr., R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann and G. von Minckwitz. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 2014. 384(9938): p. 164-72.
  5. von Minckwitz, G., M. Untch, J.U. Blohmer, S.D. Costa, H. Eidtmann, P.A. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober, C. Jackisch, M. Kaufmann, G.E. Konecny, C. Denkert, V. Nekljudova, K. Mehta and S. Loibl. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 2012. 30(15): p. 1796-804.
  6. Mieog, J.S., J.A. van der Hage and C.J. van de Velde. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev, 2007(2): p. CD005002.
  7. Berruti, A., V. Amoroso, F. Gallo, V. Bertaglia, E. Simoncini, R. Pedersini, L. Ferrari, A. Bottini, P. Bruzzi and M.P. Sormani. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol, 2014. 32(34): p. 3883-91.
  8. Liedtke, C., C. Mazouni, K.R. Hess, F. Andre, A. Tordai, J.A. Mejia, W.F. Symmans, A.M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G.N. Hortobagyi and L. Pusztai. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008. 26(8): p. 1275-81.
  9. Gianni, L., W. Eiermann, V. Semiglazov, A. Lluch, S. Tjulandin, M. Zambetti, A. Moliterni, F. Vazquez, M.J. Byakhov, M. Lichinitser, M.A. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, D. Magazzu, D. Heinzmann, J. Steinseifer, P. Valagussa and J. Baselga. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol, 2014. 15(6): p. 640-7.
  10. Gianni, L., W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vazquez, M. Byakhow, M. Lichinitser, M.A. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, R. Baronio, A. Feyereislova, C. Barton, P. Valagussa and J. Baselga. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010. 375(9712): p. 377-84.
  11. Untch, M., M. Rezai, S. Loibl, P.A. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kuhn, A. du Bois, J.U. Blohmer, C. Thomssen, S. Dan Costa, C. Jackisch, M. Kaufmann, K. Mehta and G. von Minckwitz. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 2010. 28(12): p. 2024-31.
  12. Ismael, G., R. Hegg, S. Muehlbauer, D. Heinzmann, B. Lum, S.B. Kim, T. Pienkowski, M. Lichinitser, V. Semiglazov, B. Melichar and C. Jackisch. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol, 2012. 13(9): p. 869-78.
  13. Untch, M., S. Loibl, J. Bischoff, H. Eidtmann, M. Kaufmann, J.U. Blohmer, J. Hilfrich, D. Strumberg, P.A. Fasching, R. Kreienberg, H. Tesch, C. Hanusch, B. Gerber, M. Rezai, C. Jackisch, J. Huober, T. Kuhn, V. Nekljudova, G. von Minckwitz, G. German Breast and G. Arbeitsgemeinschaft Gynakologische Onkologie-Breast Study. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 2012. 13(2): p. 135-44.
  14. Guarneri, V., A. Frassoldati, A. Bottini, K. Cagossi, G. Bisagni, S. Sarti, A. Ravaioli, L. Cavanna, G. Giardina, A. Musolino, M. Untch, L. Orlando, F. Artioli, C. Boni, D.G. Generali, P. Serra, M. Bagnalasta, L. Marini, F. Piacentini, R. D'Amico and P. Conte. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol, 2012. 30(16): p. 1989-95.
  15. Robidoux, A., G. Tang, P. Rastogi, C.E. Geyer, Jr., C.A. Azar, J.N. Atkins, L. Fehrenbacher, H.D. Bear, L. Baez-Diaz, S. Sarwar, R.G. Margolese, W.B. Farrar, A.M. Brufsky, H.R. Shibata, H. Bandos, S. Paik, J.P. Costantino, S.M. Swain, E.P. Mamounas and N. Wolmark. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol, 2013. 14(12): p. 1183-92.
  16. Baselga, J., I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, C. Aura, H. Gomez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T.W. Chang, Z. Horvath, M. Coccia-Portugal, J. Domont, L.M. Tseng, G. Kunz, J.H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R.D. Gelber, M. Piccart-Gebhart and A.S.T. Neo. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 2012. 379(9816): p. 633-40.
  17. Goss, P.E., I.E. Smith, J. O'Shaughnessy, B. Ejlertsen, M. Kaufmann, F. Boyle, A.U. Buzdar, P. Fumoleau, W. Gradishar, M. Martin, B. Moy, M. Piccart-Gebhart, K.I. Pritchard, D. Lindquist, Y. Chavarri-Guerra, G. Aktan, E. Rappold, L.S. Williams, D.M. Finkelstein and T. investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol, 2013. 14(1): p. 88-96.
  18. Gianni, L., T. Pienkowski, Y.H. Im, L. Roman, L.M. Tseng, M.C. Liu, A. Lluch, E. Staroslawska, J. de la Haba-Rodriguez, S.A. Im, J.L. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross and P. Valagussa. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012. 13(1): p. 25-32.
  19. Schneeweiss, A., S. Chia, T. Hickish, V. Harvey, A. Eniu, R. Hegg, C. Tausch, J.H. Seo, Y.F. Tsai, J. Ratnayake, V. McNally, G. Ross and J. Cortes. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013. 24(9): p. 2278-84.
  20. Swain, S.M., J. Baselga, S.B. Kim, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J.M. Ferrero, A. Schneeweiss, S. Heeson, E. Clark, G. Ross, M.C. Benyunes, J. Cortes and C.S. Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med, 2015. 372(8): p. 724-34.
  21. von Minckwitz, G., A. Schneeweiss, S. Loibl, C. Salat, C. Denkert, M. Rezai, J.U. Blohmer, C. Jackisch, S. Paepke, B. Gerber, D.M. Zahm, S. Kummel, H. Eidtmann, P. Klare, J. Huober, S. Costa, H. Tesch, C. Hanusch, J. Hilfrich, F. Khandan, P.A. Fasching, B.V. Sinn, K. Engels, K. Mehta, V. Nekljudova and M. Untch. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol, 2014. 15(7): p. 747-56.
  22. Sikov, W.M., D.A. Berry, C.M. Perou, B. Singh, C.T. Cirrincione, S.M. Tolaney, C.S. Kuzma, T.J. Pluard, G. Somlo, E.R. Port, M. Golshan, J.R. Bellon, D. Collyar, O.M. Hahn, L.A. Carey, C.A. Hudis and E.P. Winer. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol, 2015. 33(1): p. 13-21.
  23. Rugo, H., O. Olopade, A. DeMichele, L. van 't Veer, M. Buxton, N. Hylton, D. Yee, A. Chien, A. Wallace, I.-S.S. PI's, J. Lyandres, S. Davis, A. Sanil, D. Berry and L. Esserman. Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. Cancer Research, 2013. 73(24 Supplement): p. S5-02.
  24. Semiglazov, V.F., V.V. Semiglazov, G.A. Dashyan, E.K. Ziltsova, V.G. Ivanov, A.A. Bozhok, O.A. Melnikova, R.M. Paltuev, A. Kletzel and L.M. Berstein. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer, 2007. 110(2): p. 244-54.
  25. Fontein, D.B., A. Charehbili, J.W. Nortier, E. Meershoek-Klein Kranenbarg, J.R. Kroep, H. Putter, Y. van Riet, G.A. Nieuwenhuijzen, B. de Valk, J.M. Terwogt, G.D. Algie, G.J. Liefers, S. Linn and C.J. van de Velde. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial. Eur J Cancer, 2014. 50(13): p. 2190-200.
  26. Dowsett, M., I.E. Smith, S.R. Ebbs, J.M. Dixon, A. Skene, R. A'Hern, J. Salter, S. Detre, M. Hills, G. Walsh and I.T. Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 2007. 99(2): p. 167-70.

Diagnostik und Therapie des hepatozellulären Karzinoms

M. Guba und M. Schoenberg, München (S. 42)

  1. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (Leitlinienprogramm Onkologie). Diagnostik und Therapie des hepatozellulären Karzinoms: Langversion 1.0 [AWMF Registrierungsnummer: 032-053OL] [cited 2015 Sep 21]. Available from: URL: leitlinienprogrammonkologie.de/Leitlinien.7.0.html.
  2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(5 Suppl 1):S5-S16.
  3. Tanaka Y, Hanada K, Mizokami M, Yeo AET, Shih JW, Gojobori T et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proceedings of the National Academy of Sciences of the United States of America 2002; 99(24):15584–9.
  4. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Journal of hepatology 2001; 34(4):570–5.
  5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011; 53(3):1020–2.
  6. Llovet JM, Fuster J, Bruix J. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(S2):S115-S120.
  7. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12(8):1260–7.
  8. Viganò M, Bhoori S, Lampertico P, Donato MF, Iavarone M, Grossi G et al. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. Liver Int 2015; 35(9):2187–93.
  9. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W et al. Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z Gastroenterol 2011; 49(07):871–930.
  10. Burra P, Martin E de, Zanetto A, Senzolo M, Russo FP, Zanus G et al. Hepatitis C virus and liver transplantation: Where do we stand? Transpl Int 2015:n/a-n/a.
  11. Teng C, Hwang W, Chen Y, Chang K, Cheng S. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: A case control study. World J Surg Onc 2012; 10(1):41.
  12. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: Recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37(4):411–9.
  13. Jakobs TF, Hoffmann R, Poepperl G, Schmitz A, Lutz J, Koch W et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur Radiol 2007; 17(5):1320–30.
  14. Huang W, Jen Y, Lee M, Chang L, Chen C, Ko K et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. International journal of radiation oncology, biology, physics 2012; 84(2):355–61.
  15. Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World journal of hepatology 2015; 7(17):2053–7.
  16. Lee SC, Tan HT, Chung MCM. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World journal of gastroenterology : WJG 2014; 20(12):3112–24.
  17. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T-lymphocytes. Int J Oncol 2014.
  18. Kingham TP, Karkar AM, D'Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. Journal of the American College of Surgeons 2012; 215(3):379–87.